Assessing T cell fraction alongside tumor thickness was superior to other histopathological variables for accurate progression-free survival prediction.
Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.
Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
The worldwide license provides Iovance Biotherapeutics exclusive rights to Cellectis' TALEN gene editing technology for multiple gene targets to modify TILs for treating various cancers.
The company is beginning a multi-site Phase II trial designed to establish that its approach can identify patients who will respond to immuno-oncology drugs.
